Back to results
US 11,685,954 B2Granted
Biomarkers predictive of endocrine resistance in breast cancer
AssigneeDana-Farber Cancer Institute, Inc.
InventorsXiaole Liu, Myles Brown, Wei Li, Tengfei Xiao
Life of this patent
Estimating the term…
Abstract
The present invention is based on the identification of novel biomarkers predictive of endocrine resistance in breast cancer.
Claims11
A method of treating a subject afflicted with a c-Src tyrosine kinase (CSK)-null breast cancer that is resistant to an endocrine therapy comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of PAK2 that directly binds PAK2, thereby treating the subject afflicted with the breast cancer that is resistant to the endocrine therapy.
Dependencies are inferred from the claim text.